Decoy Therapeutics: Inhibitors Show Promising In Silico Activity Against Measles, Related Viruses

(RTTNews) - Decoy Therapeutics announced that a series of antiviral drug candidates previously designed by its IMP3ACT platform to be broadly effective against viruses of the paramyxoviridae family also showed promising in silico activity against measles and Nipah viruses.

"With this compound, we are developing a highly topical engineering application using Decoys platform technology and we are just getting started," said Decoys Co-founder and CEO Rick Pierce.

It was previously announced that Decoy and Salarius Pharmaceuticals, Inc. (SLRX) signed a definitive merger agreement pursuant to which Decoy will merge with a wholly owned subsidiary of Salarius.

For More Such Health News, visit rttnews.com.